Powder: -20°C for 3 years | In solvent: -80°C for 1 year
B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 44.00 | |
5 mg | In stock | $ 98.00 | |
10 mg | In stock | $ 163.00 | |
25 mg | In stock | $ 277.00 | |
50 mg | In stock | $ 397.00 | |
100 mg | In stock | $ 597.00 |
Description | B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells. |
Targets&IC50 | IRE1 Rnase:1230 nM |
In vitro | B I09 is an IRE-1 RNase inhibitor, with an IC50 of 1230 nM[1] and it also is highly effective in inhibiting splicing of XBP1 mRNA in human WaC3 cells and the expression of XBP-1s in LPS stimulated B cells[2]. Treatment of CLL cells with this inhibitor (B I09) mimick XBP-1 deficiency, including upregulation of IRE-1 expression and compromised BCR signaling. |
In vivo | B I09 exhibits a half-life of roughly 1.5 hours and achieves its maximum concentration of about 39 μM in mouse plasma serum within 15 minutes post-administration. Upon administration to mice bearing CLL tumors, B I09 effectively halts leukemic progression through apoptosis induction, without inducing systemic toxicity[2]. |
Molecular Weight | 303.31 |
Formula | C16H17NO5 |
CAS No. | 1607803-67-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 7.5 mg/mL (24.7 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
B I09 1607803-67-7 Cell Cycle/Checkpoint Others IRE1 B I-09 inhibitor inhibit